Puma Biotechnology Inc
PBYI
Company Profile
Business description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Contact
10880 Wilshire Boulevard
Suite 2150
Los AngelesCA90024
USAT: +1 424 248-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
172
Stocks News & Analysis
stocks
Palantir earnings: AI leadership intact; valuation still causes heartburn
Our view of Palantir Technologies.
stocks
As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally
Demand for AI has catapulted tech stocks into the stratosphere.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,032.90 | 57.60 | -0.63% |
| CAC 40 | 8,067.53 | 42.26 | -0.52% |
| DAX 40 | 23,949.11 | 183.30 | -0.76% |
| Dow JONES (US) | 47,085.24 | 251.44 | -0.53% |
| FTSE 100 | 9,714.96 | 13.59 | 0.14% |
| HKSE | 25,686.92 | 265.48 | -1.02% |
| NASDAQ | 23,348.64 | 486.09 | -2.04% |
| Nikkei 225 | 49,360.90 | 2,136.30 | -4.15% |
| NZX 50 Index | 13,578.79 | 27.17 | -0.20% |
| S&P 500 | 6,771.55 | 80.42 | -1.17% |
| S&P/ASX 200 | 8,770.20 | 39.60 | -0.45% |
| SSE Composite Index | 3,937.66 | 22.53 | -0.57% |